ATAI Life Sciences NV held its annual general meeting of shareholders on May 15, 2025. The shareholders approved the adoption of the Dutch statutory annual accounts for fiscal year 2024. Deloitte & Touche LLP and Deloitte Accountants B.V. were appointed as the external auditor for fiscal year 2025. Members of the supervisory and management boards were released from liability for the exercise of their duties during fiscal year 2024. The authorization of the management board to issue shares and grant rights to subscribe for shares was extended. The management board's authorization to limit and exclude pre-emption rights was also extended. Additionally, the authorization of the management board to acquire shares or depositary receipts for such shares in the company's capital was extended.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.